Funding for this research was provided by:
Bristol-Myers Squibb (CA209-814)
Received: 19 August 2019
Accepted: 18 October 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: The trial has received ethics approval from the NHS National Research Ethics Service (NRES) Yorkshire and The Humber Leeds East Research Ethics Committee (Ref: CitationRef removed/YH/0187). All participating sites require site specific approval before opening to patient recruitment. All participants provide full informed consent to participate in PRISM.
: Not applicable.
: TW, KF, JL, PN, TP and NV have received advisory fees and / or speaker honoraria from Bristol Myers Squibb. This trial is funded by Bristol-Myers Squibb, a global biopharmaceutical company. All other authors declare that they have no competing interests.